RxDoctor Payments Data

Bessie Ingram-Nunally, MD

Internal Medicine · Chattanooga, TNNPI 1720069578

Payments from drug & device makers

$1,624in general payments, 2019–2025

Across 88 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$228
  • Novo Nordisk$182
  • AstraZeneca$176
  • Astellas Pharma US Inc$147
  • E.r. Squibb & Sons, L.L.C.$133
  • Johnson & Johnson$124
  • plus $634 from 20 others

What the payments were for

  • Food & beverage$1,624100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,624 in reported general payments places this provider in the 75th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$86,589
Medicare patients
391
Services billed
1,084

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide121$117,341
JardianceEmpagliflozin48$66,134
EliquisApixaban71$64,847
FarxigaDapagliflozin Propanediol58$54,192
XareltoRivaroxaban27$32,069
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$30,710
JanuviaSitagliptin Phosphate31$27,157
MounjaroTirzepatide21$24,800
Spiriva HandihalerTiotropium Bromide29$21,539
TrulicityDulaglutide11$18,741
EntrestoSacubitril/Valsartan17$16,857
Breo ElliptaFluticasone/Vilanterol12$8,449
Tresiba Flextouch U-100Insulin Degludec17$8,258
Albuterol Sulfate HfaAlbuterol Sulfate165$6,149
Potassium Chloride279$4,800

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$182$117,341121 claims
Boehringer IngelheimJardiance$24$66,13448 claims
PfizerEliquis$228$64,84771 claims
AstraZenecaFarxiga$176$54,19258 claims
Lilly USA, LLCMounjaro, Trulicity$12$43,54232 claims
Johnson & JohnsonXarelto$124$32,06927 claims
MerckJanuvia$32$27,15731 claims
NovartisEntresto$56$16,85717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →